There seems to be no need for a booster dose in the present scenario, according to Randeep Guleria, Director of AIIMS.
This was said in the backdrop of India’s national average of first dose at 82 per cent and second dose at 43 per cent.
“When H1N1 had hit India, vaccines were imported from foreign countries. From importing vaccines to manufacturing our own indigenous vaccine, we have come a long way. Today, our vaccines are being exported to other countries,” said Guleria at the launch of the book Going Viral by Balram Bhargava, Director General of the Indian Council of Medical Research.
“The development of Covaxin was made possible with the collaboration between ICMR and Bharat Biotech. This is a true example of public-private partnership, which is marked with trust, transparency and mutual respect, said Bhargava.
Meanwhile, Health Secretary Rajesh Bhushan said: “On the personal front, we saw sadness, grief, and apprehensions during Covid. Despite all that we stuck together as a team. This is the only way we were able to develop Covaxin in record time.”
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.